220607-75-0

Basic information

• Product Name: 3,5-DIFLUOROPHENACYL BROMIDE
• Synonyms: 2-BROMO-3,5-DIFLUOROACETOPHENONE;3',5'-DIFLUOROPHENACYL BROMIDE;3,5-DIFLUOROPHENACYL BROMIDE;(R)-N-[1-(3-FLUOROPHENYL)ETHYL]METHYLAMINE, 98% MIN.;2-bromo-1-(3,5-difluorophenyl)ethanone;2-Bromo-3',5'-difluoroacetophenone, 2-Bromo-1-(3,5-difluorophenyl)ethan-1-one;Ethanone, 2-bromo-1-(3,5-difluorophenyl)-;3,5-Difluorophenacylbromide98%
• CAS NO: 220607-75-0
• Molecular Formula: C₈H₅BrF₂O
• Molecular Weight: 235.03
• Mol File: 220607-75-0.mol

Chemical Properties

• Boiling Point: 246℃
• Flash Point: 102℃
• Appearance: /
• Density: 1.649 g/cm³
• Vapor Pressure: 0.0281mmHg at 25°C
• Refractive Index: 1.529
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3,5-DIFLUOROPHENACYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DIFLUOROPHENACYL BROMIDE(220607-75-0)
• EPA Substance Registry System: 3,5-DIFLUOROPHENACYL BROMIDE(220607-75-0)

Safety Data

• Hazard Codes: C,F
• Hazardous Substances Data: 220607-75-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
3,5-Difluorophenacyl bromide is used as a reagent in pharmaceutical synthesis for the construction of carbon-carbon and carbon-heteroatom bonds. Its ability to introduce fluorine atoms into organic molecules makes it a valuable precursor in the development of various pharmaceutical compounds.
Used in Agrochemical Synthesis:
In the agrochemical industry, 3,5-Difluorophenacyl bromide is used as a reagent for the synthesis of various agrochemical compounds. Its unique structure and reactivity contribute to the development of effective and targeted agrochemical products.
Used in the Development of Anticonvulsant and Analgesic Agents:
3,5-Difluorophenacyl bromide is used as a key intermediate in the synthesis of potential anticonvulsant and analgesic agents. Its involvement in the synthesis of biologically active compounds has led to the discovery of new therapeutic options for the treatment of epilepsy and pain management.
Used in Organic Synthesis for Fine Chemicals Production:
3,5-Difluorophenacyl bromide is utilized in organic synthesis as a reagent for the production of fine chemicals. Its ability to form carbon-carbon and carbon-heteroatom bonds makes it a versatile building block in the synthesis of a wide range of specialty chemicals.

InChI:InChI=1/C8H5BrF2O/c9-4-8(12)5-1-6(10)3-7(11)2-5/h1-3H,4H2

Upstream product

• 186581-53-3 diazomethane 
• 455-40-3 3,5-difluorobenzoic acid 
• 461-96-1 3,5-difluorobromobenzene 
• 67-56-1 methanol 
• 123577-99-1 3′,5′-difluoroacetophenone 

Downstream Products

• 1346652-90-1 3-(3,5-difluorophenyl)-4,6-dimethoxybenzofuran 
• 1395931-48-2 2-(3,5-difluorophenyl)-4H-chromen-4-one 
• 1189570-10-2 (9aR)-8-allyl-7(S)-(3,5-difluorophenyl)hexahydropyrazino[2,1-c][1,4]oxazin-9(6H)-one 
• 1189570-08-8 (9aR)-8-allyl-7(R)-(3,5-difluorophenyl)hexahydropyrazino[2,1-c][1,4]oxazin-9(6H)-one 
• 1189569-40-1 (2R)-5-{(1E)-3-[(7R,9aR)-7-(3,5-difluorophenyl)-9-oxohexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]prop-1-en-1-yl}-1,3-dihydrospiro[indene-2,3 '-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 5 
• 1257388-52-5 ethyl (rac)-E/Z-{benzyl-[2-(3,5-difluorophenyl)-2-hydroxyiminoethyl]amino}-(tetrahydropyran-4-yl)acetate 
• 1257387-90-8 (2S)-tert-butyl-2-(cycloheptylmethyl)-5-(3,5-difluorophenyl)-4-(2-methoxy-2-oxoethyl)-3-oxopiperazine-1-carboxylate 

Relevant articles and documents

Synthesis and photoelectric properties of IrIIIcomplexes using fluorobenzylimidazole[2,1-b]thiazole derivatives as primary ligands

3-Methyl-6-(3,5-difluorophenyl)imidazo[2,1-b]thiazole (mdfpit) and 3-methyl-6-(3,4,5-trifluorophenyl)imidazo[2,1-b]thiazole (mtfpit) were easily prepared from thiourea, acetone, and 3,5-difluorobenzoyl bromide or 3,4,5-trifluorobenzoyl bromide. These were used as primary ligands to synthesize twelve phosphorescent IrIIIcomplexes with picolinic acid (pic), isoquinoline-3-carboxylic acid (3-IQA), quinoline-2-carboxylic acid (2-QA), 2-(pyridin-2-yl)phenol (2-ylppy), 2-(2,4-difluorophenyl)pyridine (dfppy), and pyridine-2-sulfonic acid (2-sappy) as auxiliary ligands. Their structures, photoluminescence, and electrochemical properties were investigated. Upon introducing more fluorine atoms into the benzene ring of the primary ligand, the thermal stability, photoluminescence quantum yield (PLQY), LUMO energy level, and luminous efficiency of the resulting IrIIIcomplexes are significantly improved, and the photoluminescence emission spectra are blue-shifted. Their maximum emission wavelengths are present in the range of 517-618 nm, and the luminous colors span from the green to red light region. Using the synthesized IrIIIcomplexes as emitters, LED chips based on InGaN chip excitation were developed, which showed good performances. Among all LEDs, the PLQY of the (mtfpmt)2Ir(pic) based LED is 58.4%, and the luminous efficiency is as high as 17.11 lm W?1; the luminous efficiency of the (mdfpmt)2Ir(2-QA) based LED is 3.41 lm W?1with CIE coordinates of 0.60 and 0.38, which are very similar to the saturated standard red light emission. The results demonstrate the potential of the studied IrIIIcomplexes as candidates for LED materials.

An umpolung oxa-[2,3] sigmatropic rearrangement employing arynes for the synthesis of functionalized enol ethers

An oxa-[2,3] sigmatropic rearrangement involving arynes is reported featuring the umpolung of ketones, where the C=O bond polarity is reversed. The in situ-generated sulfur ylides from β-keto thioethers and arynes undergo efficient rearrangement allowing the facile and robust synthesis of functionalized enol ethers in high yields and excellent functional group compatibility. Preliminary mechanistic studies rule out the possibility of Pummerer-type rearrangement operating in this case.

SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES

The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.

HETEROCYCLIC AZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES

The invention relates to heterocyclic compounds of formula (I) and (IV) or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention, methods of using the compositions and kits thereof in the treatment of various demyelinating and neurodegenerative diseases, including multiple sclerosis.

OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.

Practical asymmetric synthesis of a chiral piperazinone derivative

A practical asymmetric route to a chiral piperazinone derivative, a fragment of MK-3207, is reported. The amine-bearing benzylic stereocenter is introduced via an asymmetric Pd-catalyzed hydrogenation of a cyclic sulfimidate in the presence of a chiral phosphine ligand. An efficient synthesis of the hydrogenation substrate is described, together with process development of the hydrogenation step and elaboration of the resulting cyclic sulfamate product to the desired piperazinone.

PROCESS FOR MAKING CGRP RECEPTOR ANTAGONIST

The invention encompasses a novel process for making 2-[(8R)-8-(3,5-Difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]dec-9-yl]-N-[(2R)-2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl]acetamide, which is a CGRP receptor antagonist useful for the treatment of migraine, using an asymmetric phase-transfer catalysis route. The invention also encompasses an efficient and practical synthesis of the (R)-acid intermediate, and generates the benzylic stereocenter in an enantioselective manner.

PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS

The present invention relates to the identification of inventive pyrimidine-2,4,6- triones (PYT compounds) and pharmaceutical compositions thereof for treating subjects with amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The invention also provides methods of preparing the inventive PYT compounds.

Spiro Compounds As NPY Y5 Receptor Antagonists

The present invention relates to novel compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein R is an aryl or heteroaryl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano;Z1 is H, C1-C4 alkyl or F;Z is CH2, CH(C1-C4 alkyl), C(C1-C4 alkyl)2 or a bond;A is a 6-10 membered aryl or heteroaryl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; or —C(═O)—X; or —O(CH2)0-1R1;B is hydrogen or is a 5-6 membered heteroaryl, or a 4-6 membered heterocycle, or phenyl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, hydroxyl, cyano; A and B being linked via any atom;R1 is —(C1-C4)alkyl(C1-C4)alkoxy; or C3-C8 cycloalkyl; or R1 is an aryl or heteroaryl, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano; or R1 is a 4-6 membered heterocycle, which may be substituted by one or more: halogen, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano;X is OR2 or NR3R4;R2 is C1-C4 alkyl;R3 is hydrogen or together with R4 and the nitrogen form a 5-6 saturated membered ring;R4 is C3-C8 cycloalkyl; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as NPY Y5 receptor antagonists and as agents for the treatment and/or prophylaxis of eating disorders such as a binge eating disorder.

INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE THWART MYCOBACTERIAL GROWTH

Compounds which inhibit microbial growth or attenuate the virulence of pathogen microorganisms. Compounds of the invention inhibit UDP-galactopyranose mutase (UGM) and have activity as inhibitors of microbial growth of microorganisms which contain this enzyme and particularly those microorganisms in which this enzyme is responsible for the incorporation of galactofuranose residues, particularly for uridine 5'-diphosphate (UDP) galactopyranose mutase. Compounds of the invention inhibit UDP- galactopyranose mutase (UGM) and have activity to attenuate virulence of pathogenic microorganisms, including mycobacteria.